BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Drug Development

  Bradmer Pharmaceuticals Inc. Receives FDA Approval to Proceed with Phase III Clinical Trial for Neuradiab(TM)

  June 3, 2008

   · 

  5 min read
• Drug Development

  Keryx Biopharmaceuticals Announces Phase 2 Results On KRX-0401 (Perifosine) In Patients With Relapsed/Refractory Waldenstroms Macroglobulinemia At The 44th Annual Meeting Of The American Society of Clinical Oncology

  June 3, 2008

   · 

  7 min read
• Drug Development

  Cell Therapeutics, Inc. Release: Paclitaxel Poliglumex (OPAXIO(TM))/Capecitabine Regimen Well Tolerated And Active In Metastatic Breast Cancer; Results Of Phase II Investigator-Sponsored Trial Presented At American Society of Clinical Oncology Show Invest

  June 3, 2008

   · 

  4 min read
• Pharm Country

  Alzheimer’s Drug Discovery Foundation and The Association for Frontotemporal Dementias Invite Scientists to Apply for FTD Grant Award Program

  June 3, 2008

   · 

  1 min read
• Drug Development

  Rigel Pharmaceuticals, Inc. Release: Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL; Results to be Presented at Lymphoma Meeting in Lugano, Switzerland

  June 3, 2008

   · 

  5 min read
• Drug Development

  EntreMed, Inc. Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting; Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients

  June 3, 2008

   · 

  4 min read
• Drug Development

  Auxilium Pharmaceuticals Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren’s Contracture; XIAFLEX also Meets Primary Endpoint (p<0.001) in Australian CORD II Phase III Stud

  June 3, 2008

   · 

  14 min read
• Business

  Following Positive Results Vivalis and Bavarian Nordic Extend the EBx(R) Research Licence

  June 3, 2008

   · 

  1 min read
• Drug Development

  Anadys Pharmaceuticals, Inc. Initiates Phase I Clinical Trial of ANA598 Company Developing Non-Nucleoside Polymerase Inhibitor for Treatment of Hepatitis C

  June 3, 2008

   · 

  6 min read
• Drug Development

  Rigel Pharmaceuticals, Inc. to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

  June 3, 2008

   · 

  2 min read